ArticleOncology2016
Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer.
Article in Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 34 citations in OpenAlex.
- Trial
- Prevalence of self-reported pain in patients 5 years after rectal cancer treatment: results from the prospective QoLiRECT cohort study.Acta oncologica (Stockholm, Sweden) · 2026Article
- Chemotherapy-Induced Peripheral Neuropathy (CIPN): A Narrative Review and Proposed Theoretical Model.Cancers · 2024Review
- Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system.Frontiers in pharmacology · 2024Article
- The Value of In Vivo Reflectance Confocal Microscopy as an Assessment Tool in Chemotherapy-Induced Peripheral Neuropathy: A Pilot Study.The oncologist · 2022Article
- Sociodemographic, Clinical, Lifestyle, and Psychological Correlates of Peripheral Neuropathy among 2- to 12-Year Colorectal Cancer Survivors.Oncology research and treatment · 2022Article
- Preclinical evidence for mitochondrial DNA as a potential blood biomarker for chemotherapy-induced peripheral neuropathy.PloS one · 2022Article
- Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity.Journal of personalized medicine · 2021Review
- Characterization of chemotherapy-induced peripheral neuropathy using patient-reported outcomes and quantitative sensory testing.Breast cancer research and treatment · 2021Article
- Recent advances in understanding chemotherapy-induced peripheral neuropathy.F1000Research · 2020Review
- Mechanisms, Predictors, and Challenges in Assessing and Managing Painful Chemotherapy-Induced Peripheral Neuropathy.Seminars in oncology nursing · 2019Review
- Cancer-Related Neuropathic Pain.Cancers · 2019Review
- Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations.Neurology · 2018Review
- Article
- Pain in Platin-Induced Neuropathies: A Systematic Review and Meta-Analysis.Pain and therapy · 2018Review
- Risk prediction and impaired tactile sensory perception among cancer patients during chemotherapy.Revista latino-americana de enfermagem · 2018Article
- The Potential Role of Sensory Testing, Skin Biopsy, and Functional Brain Imaging as Biomarkers in Chronic Pain Clinical Trials: IMMPACT Considerations.The journal of pain · 2017Review
- Cancer and treatment-related symptoms are associated with mobility disability in women with ovarian cancer: A cross-sectional study.Gynecologic oncology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveWe examined the emergence of chemotherapy-induced peripheral neuropathy (CIPN), a dose-limiting toxicity of oxaliplatin, over the course of oxaliplatin-based chemotherapy for colorectal cancer (CRC). Predicting which patients will likely develop CIPN is an ongoing clinical challenge.
methodsOxaliplatin-naïve patients with CRC underwent quantitative sensory testing (QST) before beginning oxaliplatin-based chemotherapy and then rated CIPN-related symptoms via the MD Anderson Symptom Inventory (MDASI) weekly for 26 weeks. Mixed modeling examined the value of QST for predicting higher CIPN (MDASI numbness/tingling) during treatment. Trajectory analysis identified a patient subgroup with consistently higher CIPN symptoms.
resultsNumbness/tingling was the most frequent, most severe symptom, with 51% of patients clustering into a high CIPN subgroup. Touch sensation deficits (Bumps Detection test) significantly predicted the development of more severe numbness/tingling [estimate (est) = 0.106, p = 0.0003]. The high CIPN subgroup reported increased pain (est = 0.472, p < 0.0001) and interference with walking (est = 0.840, p < 0.0001). In the high CIPN subgroup, patient-reported numbness/tingling worsened rapidly in weeks 0-5 (est = 0.57, p < 0.0001) and then more gradually in weeks 6-26 (est = 0.07, p < 0.0001).
conclusionPrechemotherapy screening with a simple, easily administered objective measure of touch sensation deficits (Bumps Detection test) and monitoring of patient-reported numbness/tingling during the first 2-3 chemotherapy cycles may support improved personalized care of CRC patients with oxaliplatin-induced CIPN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.